In terms of frame shifting insertion and deletion, these JAK2- and MPL-exclusive mutations were found to present in 30% to 40% of ET and PMF patients and were considered highly likely to be integrated into the next version of MPN diagnostic criteria [[13],[14]]. The gene discussed is MPL; the disease is myeloproliferative disorder.